<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05024695</url>
  </required_header>
  <id_info>
    <org_study_id>ISM06</org_study_id>
    <nct_id>NCT05024695</nct_id>
  </id_info>
  <brief_title>Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma.</brief_title>
  <acronym>STAR-V</acronym>
  <official_title>A Prospective, Multicenter Masked Clinical Trial to Evaluate the Safety and Effectiveness of the MINIject CS627 Implant in Subjects With Open Angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iSTAR Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>iSTAR Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the safety and effectiveness of iSTAR Medical's MINIject™ implant for lowering&#xD;
      intraocular pressure (IOP) in subjects with primary open-angle glaucoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, masked clinical trial to evaluate the safety and&#xD;
      effectiveness of iSTAR Medical's MINIject™ implant for lowering intraocular pressure (IOP) in&#xD;
      subjects with primary open-angle glaucoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2021</start_date>
  <completion_date type="Anticipated">March 2027</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The MINIject™ SO627 is an integrated system for Minimally Invasive Glaucoma Surgery (MIGS) comprised of a glaucoma drainage implant, the MINIject™ SO627 and the SO Delivery System, designed to deliver the MINIject™ implant into the supraciliary space. The MINIject™ SO627 implant is manufactured from proprietary STAR® silicone material.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Person(s) checking intraocular pressures are masked, except for day of surgery, throughout the duration of the trial.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure decrease</measure>
    <time_frame>24 months</time_frame>
    <description>Proportion of subjects with ≥ 20% decrease (responders) from Baseline in unmedicated DIOP at Month 24.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraocular pressure decrease (outcome 2)</measure>
    <time_frame>24 months</time_frame>
    <description>Change from baseline in mean unmedicated diurnal IOP at Month 24.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">975</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Implant Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MINIject™ Implant</intervention_name>
    <description>The MINIject™ SO627 is an integrated system for Minimally Invasive Glaucoma Surgery (MIGS) comprised of a glaucoma drainage implant, the MINIject™ SO627 and the SO Delivery System, designed to deliver the MINIject™ implant into the supraciliary space.</description>
    <arm_group_label>Implant Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Males and females, 46 years of age or older&#xD;
&#xD;
          -  A diagnosis of primary open-angle glaucoma, who are candidates for medical therapy,&#xD;
             laser treatment, or glaucoma-filtering surgery&#xD;
&#xD;
          -  Pseudophakic with prior uncomplicated cataract surgery&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Angle closure, congenital, or secondary glaucoma&#xD;
&#xD;
          -  Diagnosed degenerative visual disorders&#xD;
&#xD;
          -  Clinically significant intraocular inflammation or infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>46 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abhi Vilupuru, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>iSTAR Medical</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Abhi Vilupuru, Ph.D</last_name>
    <phone>714-914-5527</phone>
    <email>abhi.vilupuru@istarmed.us</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vold Vision</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steve Vold</last_name>
    </contact>
    <investigator>
      <last_name>Steve Vold, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <keyword>MIGS</keyword>
  <keyword>primary open angle glaucoma</keyword>
  <keyword>suprachoroidal space</keyword>
  <keyword>supraciliary space</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

